Literature DB >> 1988363

Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer.

M H Schuessler1, S Pintado, S Welt, F X Real, M Xu, M R Melamed, K O Lloyd, H F Oettgen.   

Abstract

Expression of blood-group antigens A, B, Le(a), sialyl-Le(a) (sLe(a)), Le(b), Le(x), Le(y), precursor type I, Tn and sialyl-Tn (sTn) was examined in non-neoplastic pancreas (n = 37) and pancreas cancer (n = 21) using mouse monoclonal antibodies (MAbs). Immunohistochemical assays were performed on sections of paraffin-embedded tissues using the avidin-biotin complex method. In normal pancreas, antibodies detecting Le(a), sLe(a) and Tn reacted with ductal epithelium, and antibodies detecting A and B reacted with acini and ducts, independently of secretor status. Le(x) was weakly expressed in ducts and acini, and sTn could not be detected in normal pancreas. Expression of Le(b), Le(y) and precursor type I was regulated by secretor status: Le(b) and Le(y) were expressed in ducts of secretor and Le(a-b-) individuals, but not in ducts of non-secretors; precursor type I was weakly expressed in acini and ducts of non-secretors and Le(a-b-) individuals, and was absent in acini and ducts of secretors. The following alterations in the expression of blood-group antigens were observed in pancreas cancer: (1) enhanced expression of Le(x), Tn and sTn; (2) enhanced expression of precursor type I independently of secretor status; (3) loss of regulation of Le(b) by the secretor gene; (4) decreased expression of Le(y). The weak expression of precursor type I. Tn and sTn in non-neoplastic pancreas, and their stronger expression in pancreas cancer, suggests that up-regulation of their expression is associated with malignant transformation of pancreatic duct cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988363     DOI: 10.1002/ijc.2910470204

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.

Authors:  Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

Review 2.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

4.  Fucosylation is associated with the malignant transformation of intraductal papillary mucinous neoplasms: a lectin microarray-based study.

Authors:  Kiminori Watanabe; Masayuki Ohta; Kazuhiro Yada; Yoko Komori; Yukio Iwashita; Kenji Kashima; Masafumi Inomata
Journal:  Surg Today       Date:  2016-01-11       Impact factor: 2.549

5.  Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody (MLS128) in normal and malignant tissues of the digestive tract.

Authors:  G Ohshio; T Imamura; M Imamura; H Yamabe; H Sakahara; H Nakada; I Yamashina
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 6.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

7.  Differential expression of the cancer associated antigens T (Thomsen-Friedenreich) and Tn to the skin in primary and metastatic carcinomas.

Authors:  J Kanitakis; I al-Rifai; M Faure; A Claudy
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

8.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

9.  ABO blood group and the risk of pancreatic cancer.

Authors:  Brian M Wolpin; Andrew T Chan; Patricia Hartge; Stephen J Chanock; Peter Kraft; David J Hunter; Edward L Giovannucci; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2009-03-10       Impact factor: 13.506

10.  Intermediate filaments as differentiation markers of normal pancreas and pancreas cancer.

Authors:  M H Schüssler; A Skoudy; F Ramaekers; F X Real
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.